Although the cardinal features of Parkinson's disease (PD) are motor symptoms, PD also causes cognitive deficits including cognitive flexibility and working memory, which are strongly associated with prefrontal cortex (PFC) functions. Yet, early stage PD is not characterized by pathology in the PFC but by a loss of dopaminergic (DA) projections from the substantia nigra to the dorsal striatum. Moreover, the degree to which PD symptoms can be ascribed to the loss of DA alone or to the loss of DA neurons is unknown. We addressed these issues by comparing mouse models of either chronic DA depletion or loss of DA projections to the dorsal striatum. We achieved equal levels of striatal DA reduction in both models which ranged from mild (~25%) to moderate (~60%). Both models displayed DA concentration-dependent reductions of motor function as well as mild deficits of cognitive flexibility and working memory. Interestingly, whereas both motor function and cognitive flexibility were more severely impaired after mild ablation of DA neurons as compared to mild loss of DA alone, both models had equal deficits after moderate loss of DA. Our results confirm contributions of nigro-striatal dopamine signaling to cognitive behaviors that are affected in early stage PD. Furthermore, our findings suggest that the phenotype after ablation of DA neurons accrues from factors beyond the mere loss of DA.
Introduction
A principal characteristic of PD is the degeneration of midbrain DA neurons in the substantia nigra pars compacta (SNpc) and the resulting loss of DA projections to the dorsal striatum, which contributes to the hallmark motor symptoms of the disease (Samii et al., 2004) . However, there is substantial clinical evidence for psychiatric and cognitive symptoms in PD patients (Aarsland et al., 2009; Foltynie et al., 2004; Williams-Gray et al., 2007) . Cognitive symptoms include deficits in visuospatial function, working memory, attention processes and cognitive flexibility (Giraudo et al., 1997; Lima et al., 2008; Owen et al., 1997; Sawamoto et al., 2008) . Whereas these cognitive domains are thought to be regulated by processes involving primarily the PFC, cognitive impairment is already apparent at stages of PD when pathological changes are apparent in the SNpc but have not yet extended to the PFC (Aarsland et al., 2009; Braak et al., 2003; Williams-Gray et al., 2007) . Data from rodents with neurotoxic lesions of nigro-striatal DA neurons indicate that the dorsal striatum contributes to visuospatial function and memory (Baunez and Robbins, 1999; Chudasama and Robbins, 2006; Da Cunha et al., 2002; De Leonibus et al., 2007; Mura and Feldon, 2003) . This raises the possibility that DA projections from the SNpc to the dorsal striatum not only contribute to the well-known motor symptoms but also to cognitive impairment in PD. Although DA-related dysfunction in PD is traditionally attributed to the loss of DA signaling, the actual loss of SNpc DA neurons might affect processes beyond the mere loss of DA, including inflammatory responses, gliosis and loss of co-transmitter release from DA neurons. Yet, present models for PD do not distinguish the effects of DA depletion versus loss of DA neurons on motor or cognitive dysfunction.
Our lab has generated a genetic model, the conditional Th knock-out (KO) mouse that permits depletion of DA synthesis while leaving DA neurons otherwise intact (Jackson et al., 2012) . Th alleles in these conditional KO mice can be inactivated in a region-specific manner through retrograde transport from the site of injection of a Cre recombinaseexpressing virus, CAV2-Cre (Hnasko et al., 2006) . By injecting either CAV2 Cre or the DA-specific neurotoxin 6-hydroxydopamine (6-OHDA) into the dorsal striatum we examined the consequences of disrupting DA synthesis versus loss of DA neurons to motor behaviors, visuospatial function, cognitive flexibility and working memory. Because both models of DA depletion allow for control of the loss of striatal dopamine, we can recapitulate in our mice the varying degrees of DA loss present at earlier and further advanced stages of PD, hence accounting for disease progression. 
